We revealed that RDH13, CLDN11, TMTC1, UCHL1, and FOXP2 can serve as predictive biomarkers for gastric cancer treatment and the promoter methylation level of these five genes in serum could have prognostic and diagnostic functions in gastric cancer patients. This evidence concerns the gene RDH13 and gastric cancer.